lung disease
Biodesix Prices $55M Common Stock Offering, Private Placement
The offering and concurrent private placement are expected to close on or around April 9, subject to the satisfaction of customary closing conditions.
In a bid to expand recognition and treatment of alpha-1 antitrypsin deficiency, a cause of COPD, Grifols is making its over-the-counter genetic test available for free.
New publications have expanded the discussion around the Envisia lung disease test as the firm builds evidence for its recently launched lung cancer nasal swab assay.
NASA increasingly believes the platform could be used in the medical arena.
Three Investment Banks Initiate Coverage of Biodesix
William Blair, Canaccord Genuity, and BTIG on Monday initiated coverage of newly public Biodesix, with ratings ranging from Buy to Outperform.
Dec 12, 2019
SQI Diagnostics Q4 Revenues Rise 14 Percent
Aug 28, 2019
SQI Diagnostics Q2 Revenues Tick Up Sharply
Feb 25, 2019
Aug 3, 2018